Key Points
- The US FDA has mandated warning labels on GLP-1 weight-loss medications like Wegovy and Mounjaro due to a rare risk of non-arteritic anterior ischemic optic neuropathy, also known as 'eye stroke.'
- South Korea's drug safety agency previously added vision impairment warnings to Wegovy after a local report and is now reviewing whether to expand warnings across other GLP-1 treatments.
- While a direct causal link remains unproven, clinical trial data showed roughly 6.4 cases per 100,000 users annually, prompting authorities and experts to advise prompt ophthalmic checks upon experien
Summary The global obsession with GLP-1 weight-loss injections like Wegovy and Mounjaro has encountered a serious safety checkpoint. Health regulators in the United States have officially required manufacturers to add a warning label highlighting the rare risk of sudden vision loss associated with these blockbuster medications.
The condition in question is non-arteritic anterior ischemic optic neuropathy (NAION), often referred to by medical professionals as an "eye stroke." NAION occurs when blood flow to the optic nerve is compromised, causing painless deterioration of eyesight or even total blindness in one eye. An FDA analysis of randomized controlled clinical trials revealed that approximately 6.4 out of 100,000 patients on GLP-1 drugs developed the optic neuropathy per year—a statistically higher incidence rate compared to control groups. While a direct causal link has yet to be definitively established, individuals with specific anatomical optic nerve variations, nocturnal low blood pressure, or sleep apnea appear to face an elevated risk.
In South Korea, where Wegovy recently made its highly publicized debut, the craze surrounding injectable weight-loss treatments has swept across social media, private clinics, and diet communities. However, safety concerns had already begun surfacing locally: following a suspected case of vision impairment reported in December 2024, the Ministry of Food and Drug Safety (MFDS) mandated that Wegovy include warnings regarding vision damage starting early last month. With the FDA's latest move expanding scrutiny across the broader GLP-1 drug class, South Korean health authorities are now reviewing whether to extend mandatory warnings to competing treatments such as Mounjaro.
Medical experts emphasize vigilance over panic. Specialists recommend that anyone experiencing changes in visual acuity seek immediate ophthalmic evaluation, while noting that patients who clinically require GLP-1 therapies need not unnecessarily discontinue treatment without consulting their physicians.
Sponsored · Ad